IFW 3935

MAY 9 0 2006 W

Attorney's Docket No.: 03764.P025

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Patent Application of:

Eric D. Peterson, et al.

Application No: 09/506,081

Filing Date: February 16, 2000

For: MULTI-LUMEN FLUTED

BALLOON RADIATION CENTERING

CATHETER

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Examiner:

John P. Lacyk

Art Unit:

3735

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a copy of Information Disclosure Citation Form PTO-1449 or PTO/SB/08 together with copies of the documents cited on that form, except for copies not required to be submitted (e.g., copies of U.S. patents and U.S. published patent applications need not be enclosed). It is respectfully requested that the cited documents be considered and that the enclosed copy of Information Disclosure Citation Form PTO-1449 or PTO/SB/08 be initialed by the Examiner to indicate such consideration and a copy thereof returned to applicant(s).

FIRST CLASS CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on May 25, 2006 Date of Deposit Trina Chau 05/31/2006 NNGUYEN1 000000058 09506081 Name of Person Mailing Correspondence 01 FC:1806 May 25, 2006 Date

Pursuant to 37 C.F.R. § 1.97, the submission of this Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed as an admission that the information cited in this statement is material to patentability.

Pursuant to 37 C.F.R. § 1.97, this Information Disclosure Statement is being submitted under one of the following (as indicated by an "X" to the left of the appropriate paragraph):

- X 37 C.F.R. §1.97(c). If so, then enclosed with this Information Disclosure Statement is one of the following:
 - A statement pursuant to 37 C.F.R. §1.97(e) or
 - \underline{X} A check for $$\underline{180.00}$ for the fee under 37 C.F.R. $$\underline{1.17}(p)$.

37 C.F.R. §1.97(d). If so, then enclosed with this Information Disclosure Statement are the following:

- (1) A statement pursuant to 37 C.F.R. §1.97(e); and
- (2) A check for \$180.00 for the fee under 37 C.F.R. §1.17(p) for submission of the Information Disclosure Statement.

If there are any additional charges, please charge Deposit Account No. 02-2666.

Respectfully submitted,

BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN LLP

Dated: May 25, 2006

Mimi Diemmy Dao

Reg. No. 45,628

12400 Wilshire Blvd. Seventh Floor Los Angeles, CA 90025 (408) 720-8300 MAY 9 0 2006

Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Com	nplete if Known	
Application Number	09/506,081	
Filing Date	February 16, 2000	
First Named Inventor:	Eric D. Peterson, et al.	
Art Unit	3735	
Examiner Name	John P. Lacyk	
Attorney Docket Number	03764 P025	

Sheet	1 of 5 Attorney Docket Number 03764.P025		03764.P025				
				NON PATENT LIT	ERATURE DOCUMENTS		
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					
	STUART LINDSAY et al., "Aortic Arteriosclerosis in The Dog After Localized Aortic X-Irradiation", Circulation Research, Vol. X, pp. 51-60, January 1962. MEYER FRIEDMAN et al., "The Antiatherogenic Effect of Iridium 192 Upon the Cholesterol-Fed Rabbit", Journal of Clinical Investigation, Vol. 43, No. 2, pp. 185-192, 1964.						
	MEYER FRIEDMAN et al., "Effect of Iridium ¹⁹² Radiation on Thromboatherosclerotic Plaque in the Rabbit Aorta", <u>Arch Path</u> , Vol. 80, pp. 285-290, September 1965.						
	PAUL JACK HOOPES, D.V.M., Ph.D., et al., "Intraoperative Irradiation of the Canine Abdominal Aorta and Vena Cava", Int. J. Radiation Oncology Biol. Phys., Vol. 13, pp. 715-722, May 1987. JOHN T. DAWSON, JR., M.D., "Theoretic Considerations Regarding Low-Dose Radiation Therapy", Texas Heart Institute Journal, Vol. 18, No. 1, pp. 4-7, 1991. ROBERT S. SCHWARTZ, M.D., et al., "Effect of External Beam Irradiation on Neointimal Hyperplasia After Experimental Coronary Artery Injury", JACC, Vol. 19, No. 5, pp. 1106-1113, April 1992. JOSEPH G. WIEDERMANN, M.D., et al., "Intracoronary Irradiation Markedly Reduces Restenosis After Balloon Angioplasty in a Porcine Model", JACC, Vol. 23, No. 6, pp. 1491-1498, May 1994.						
						ow-Dose Radiation	
	TIM A. FISCHELL, M.D., et al., "Low-Dose B-Particle Emission from 'Stent' Wire Results in Complete, Localized Inhibition of Smooth Muscle Cell Proliferation", Circulation, Vol. 90, No. 6, pp. 2956-2963, December 1994. MARIA G. M. HUNINK, M.D., et al., "Risks and Benefits of Femoropopliteal Percutaneous Balloon Angioplasty", Journal of Vascular Surgery, Vol. 17, No. 1, pp. 183-194, January 1993. RON WAKSMAN, M.D., et al., "Endovascular Low-Dose Irradiation Inhibits Neointima Formation After Coronary Artery Balloon Injury in Swine", Circulation, Vol. 91, No. 5, pp. 1533-1539, March 1, 1995.						
					ion of Smooth Muscle Cell Pro Radiation Biology, pp. 133-138		

Examiner	Date	
Signature	Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

(WAY 0 0 2000 %)
Substitute for Form 1449/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT (use as many sheets as necessary)

Complete if Known				
Application Number	09/506,081			
Filing Date	February 16, 2000			
First Named Inventor:	Eric D. Peterson, et al.			
Art Unit	3735			
Examiner Name	John P. Lacyk			
Attorney Docket Number	02764 D025			

				,				
Sheet	2 of 5 Attorney Docket Number 03764.P025							
				NON PATENT LIT	ERATURE DOCUMENTS	3		
Examiner Initials*	Cite No ¹							
		C. HEHRLE pp. 63-64, .			s", <u>Discoveries in Radiatio</u>	on for Restenosis, Abstract 22,		
					Particle Emitting Radioisor Restenosis, Abstract 23	tope Stent for the Prevention of , p. 65, January 1996.		
						tment of Coronary Artery , pp. 67-72, January 1996.		
		RON WAKSMAN, M.D., "Catheter-Based Radiation in Stented Arteries", <u>Discoveries in Radiation for Restenosis</u> , Abstract 25, pp. 73-74, January 1996.						
					Peripheral Applications: , pp. 81-82, January 1996	Technical Aspects", <u>Discoveries</u>		
					enosis in Peripheral Vasc p. 83-88, January 1996.	ular Disease", <u>Discoveries in</u>		
		Implantation	n in Peripi			Recurrent Stenosis After Stent s in Radiation for Restenosis,		
		RON WAKS	SMAN, M.		e Peripheral System at Er lanuary 1996.	nory", <u>Discoveries in Radiation</u>		
					estenosis Trials Using Be Abstract 32, pp. 101-102			
				., et al., "Endovasc act 33, pp. 103-104		vire", <u>Discoveries in Radiation</u>		
		Angioplasty	(PTCA) a			ransluminal Coronary <u>Discoveries in Radiation for</u>		

Examiner	Date	
Signature	Considered	

'Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for Form 1449/PTO	Complete if Known

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE			I OSHRE	Application Number	09/506,081			
					Filing Date	February 16, 2000		
STATEMENT BY APPLICANT			₽LICANT%ৄ∖	First Named Inventor:	Eric D. Peterson, et al.			
	(use as many sheets as necessary) AN 3 0 2006			SSARX) X 3 0 2006	Art Unit	3735	_	
	_			B S	Examiner Name	John P. Lacyk		
Sheet		3	of	Remanda Nove S	Attorney Docket Number	03764.P025		
				NON PATENT LIT	ERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published						
		Restenosis,	Abstract	t 35, p. 111, Januar				
				Fet al., "HDR Afterl t 36, p. 113, Januar	oader for Vascular Use", <u>Disco</u> y 1996.	veries in Radiation for		
					lioisotope Stent: Conception ar , Abstract 37, p. 115, January 1			
					pactive Wire in Self-Centering , Abstract 38, pp. 117-118, Jan			
					se Rate Afterloader System for Restenosis, Abstract 39, p. 11			
		DR. EDWARD F. SMITH III, "Issues on Handling Radioactive Devices to Prevent Restenosis", Discoveries in Radiation for Restenosis, Abstract 40, pp. 121-122, January 1996.						
					eralized Model of Restenosis A herectomy", <u>JACC</u> , Vol, 21, No			
					ntial Neointimal Response to C rombosis, Vol. 14, No. 3, pp. 3			
	MICHAEL HAUDE, M.D., et al., "Quantitative Analysis of Elastic Recoil after Balloon Angioplasty and After Intracoronary Implantation of Balloon-Expandable Palmaz-Schatz Stents", <u>JACC</u> , Vol. 21, No. 1, pp. 26-34, January 1993.							
		WILLIAM S.	WEINT	RAUB, M.D., et al.,	"Can Restenosis After Coronar CC, Vol. 21, No. 1, pp. 6-14, Ja	, , ,		
		Intimal Form Model, <u>Circu</u>	ation, Ad <u>Ilation,</u> V	ccount for Restenos ol. 89, No. 6, pp. 28	fferences in Compensatory Versis After Angioplasty in the Hyp 309-2815, June 1994.	ercholesterolemic Rabbit		
			Neointim	al Proliferation After	"Reduced Acute Thrombus For Coronary Angioplasty", <u>JACC</u>			

Examiner	Date	
Signature	Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

						· · · · · · · · · · · · · · · · · · ·		
Substitute	for Fo	rm 1449/PTO			Complete if Known			
INF)RN	NOITAN	DISCLA	SEURF	Application Number	09/506,081		
INFORMATION DISCLOSURE STATEMENT BY APPLICAN'S				Filing Date	February 16, 2000			
SIA	ΛΙΕΊ	MENIB	YAPPL	ICAN &	First Named Inventor:	Eric D. Peterson, et al.		
	(us	se as many shee	ts as necessary MA	3 0 2006	Art Unit	3735		
	,		\ <u>\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\</u>	<u> </u>	Examiner Name	John P. Lacyk		
Sheet	<u> </u>	4	of V	CONTRACTOR OF THE PARTY OF THE	Attorney Docket Number	03764.P025		
			NO	N PATENT LIT	ERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	(book, m	agazine, journ	nal, serial, sympos publisher, city	ETTERS), title of the article (when sium, catalog, etc.), date, page(s), and/or country where published	volume-issue number(s),	T ²	
					Radiation Safety in the Cardia vascular Diagnosis, Vol. 25, pp			
				et al., "The Hear 277-284, Janua	t and Blood Vessels", <u>Radiatio</u> ry 1996.	n Oncology Rationale,		
		C. G. SOARES et al., "Measurement of Radial Dose Distributions Around Small Beta Particle Emitters Using High Resolution Radiochromic Foil Dosimetry" <u>Nuclear Technology Publishing</u> , Vol. 4, No. 1, pp. 367-372, 1992.						
			al Procedure		itial Biological Effects Following ascular and Interventional Rad			
		Formation A	fter Coronar		nary Low-Dose <i>B</i> -Irradiation Ir Injury in Swine Restenosis Mo 1955.			
		JOSEPH G. WIEDERMANN, M.D., et al., Intracoronary Irradiation Markedly Reduces Neointimal Proliferation After Balloon Angioplasty in Swine: Persistent Benefit at 6-month Follow-up", <u>JACC</u> , Vol. 25, No. 1, pp. 1451-1456, May 1995.						
		Hyperplasia Interventiona	After Stent In al Radiology,	mplantation in F Vo. 17, pp. 12-		ovascular and		
		KEITH L. MARCH, M.D., et al., "8-Methoxypsoralen and Longwave Ultraviolet Irradiation are a Novel Antiproliferative Combination for Vascular Smooth Muscle", <u>Circulation</u> , Vol. 87, No. 1, pp. 184-191, January 1993. BARRY T. KATZEN, M.D., "Mechanical Approaches to Restenosis in the Peripheral Circulation", January 1996.						
		Hyperchloes October 15,	terolemic Ra 1995.	abbit Restenosis	I Beta Irradiation Prevents Nec Model", <u>Circulation</u> , Vol. 92, N	No.8, pp. 2284-2290,		
			ormation in S	Stented Porcine	nary Radiation Before Stent In Coronary Arteries", Circulation			

Examiner	Date	
Signature	Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VIrgInla 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VIrgInla 22313-1450.

Substitute for Form 4440/DTO			Complete is Warrant							
Substitute for Form 1449/PTO					Complete if Known					
STATEMENT BY APPLICANT			Application Number		09/506,081					
			Filing Date \First Named Inventor:		February 16, 2000					
2006					Art Unit	3735	Eric D. Peterson, et al.			
				/ MAY	Examiner Name		vde			
Sheet	T	5	of	Te o SABEMENT	Attorney Docket Number	John P. Lac 03764.P025				
Sileet	<u> </u>	3				03764.P025)			
NON PATENT LITERATURE DOCUMENTS										
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published								
		CHRISOPH HEHRLEIN, M.D., et al., "Low-Dose Radioactive Endovascular Stents Prevent Smooth Muscle Cell Proliferation and Neointimal Hyperplasia in Rabbits", <u>Circulation</u> , Vol. 92, No. 6, pp. 1570-1575, September 15, 1995.								
		PCT Search Report PCT/US99/03327 mailed June 18, 1999								
		PCT Search Report PCT/US99/03343 mailed June 17, 1999								
		PCT Search Report PCT/US99/03328 mailed June 18, 1999								
,		PCT Search Report PCT/US99/03329 mailed June 18, 1999								
		PCT Search Report PCT/US99/03360 mailed June 17, 1999								
		PCT Search	Report fo	or PCT/US01/05136	5, mailed June 20, 2001	<u>.</u>				
		1 01 ocaion	rreportie	,	5, manea dane 25, 250 i					
					· · · · · · · · · · · · · · · · · · ·					
								<u></u>		
Examiner		· —— .				Date				

copy of this form with next communication to applicant.

Signature Considered *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time your require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.